

## **Amir Heydari**

Department of Pharmacology  
School of Pharmacy  
Urmia University of Medical sciences, Urmia ,Iran

Phone: +984432754991, email:heydari.866@gmail.com

---

### **EDUCATION**

**The University of Sheffield**, Sheffield, United of Kingdom, PhD in Pharmacology, 2005

**Tabriz University of Medical Sciences**, Tabriz, Iran , Pharm. D in Pharmacy 1985

### **EMPLOYMENT**

**Associate Professor**, School of Pharmacy, Urmia University of Medical sciences, Urmia ,Iran

Simcyp Company (United Kingdom), Designing Software to predict drug-drug interactions using *in vitro* data

Responsibility of Continuing Medical Education at the Urmia medical University

### **PUBLICATIONS**

**Heydari A.**, Rowland Yeo K., Lennard M.S., Ellis S.W., Tucker G. T., Rostami-Hodjegan A., Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. *Drug Metabolism and Disposition*. 32 (11): 1213-1217 (2004)

Yang J.S., Jamei M., **Heydari A.**, Rowland Yeo K., De la Torre R., Farre M., Tucker G. T., Rostami-Hodjegan A., Implications of Mechanism-Based Inhibition of CYP2D6 for the Pharmacokinetics and Toxicity of MDMA, *Journal of Psychopharmacology* (2006)

Van L.M., **Heydari A.**, Hargreaves J., Rowland Yeo K., Lennard M.S., Tucker G.T., Rostami-Hodjegan A., The impact of experimental design on assessing mechanism-based inhibition of CYP2D6 inactivation by MDMA (Ecstasy), *Journal of Psychopharmacology* (2005)

**Heydari A.**, Samarai V., Determination of Ciprofloxacin in ocular aqueous by High Performance Liquid Chromatography, Comparison of topical and Combination of topical and oral administration., *Iranian Journal of Ophthalmology* (2011)

Akbari A, **Heydari A.**, Determining the quality of Ciprofloxacin in pharmaceutical formulations (Tablets, Eye drops and Infusion solutions) using HPLC method with fluorescence detection, *The journal of Urmia nursing and midwifery faculty*, Vol 12(4), June, 2014

**Heydari A.**, Peirouvi T, Akbari A, Mahmoodlou R, Preparing Microsomes and Measuring its Protein in human liver samples, *Journal of Sabzevar University of Medical Sciences*, volume 22, number 2, May & June 2015

**Heydari A.**, Vardast MR, Yeganeh Zare S, An improved simple and precise HPLC method for determination of folic acid in fortified wheat flours and breads with fluorescence detection, *The journal of Urmia University of Medical Sciences*, Vol. 25(12), February 2015

Ghafari R, **Heydari A.**, Vardast MR, Akbari A, HPLC measurement of MDMA Content in Ecstasy Tablets Available in the Black Market of West Azarbaijan Province, Northwestern Iran, *Asia Pacific Journal of Medical Toxicology*, December 2014

**Heydari A.**, Akbari A, Peirouvi T. Determination of dextromethorphan in pharmaceutical formulations available in pharmaceutical formulation available in drug market of Iran using HPLC method. , *The journal of Urmia University of Medical Sciences*, 2013; 24 (6) :405-413

Akbari A, **Heydari A.** Quantification of oxytocin in pharmaceutical dosage forms available in drug market of Iran by using high performance

liquid chromatography method ( HPLC), *The journal of Urmia University of Medical Sciences*,2014; 24 (12) :956-965

Peirouvi T, **Haidary A**, Solati M, Mohammadnejad D, Gharbali A, Farjah G. Histological Effects of GnRH Agonist on Epididymal Tissues in Prepubertal Rat . 3. 2012; 19 (1) :52-58

### **Manuscript in preparation from completed research**

**Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Lennard M.S., Tucker G.T., Prediction of *in vivo* drug-drug interactions involving SSRIs (selective serotonin reuptake inhibitors) from *in vitro* data by Simcyp<sup>®</sup>

## **CONFERENCES**

### **Oral presentation**

**Heydari A.**, Rostami-Hodjegan A., Lennard M.S., De la Torre R., Tucker G.T., Farre M., Inactivation of CYP450 2D6 by ecstasy: Implications for frequency of dosage (Harrogate), **Lilly Fellowship Awards**. *Journal of Psychopharmacology* 16 (3): G12 Suppl. S SEP 2002

**Heydari A.**, Yang.J.S., Rostami-Hodjegan A. Prediction of *in vivo* interaction between Zolpidem and Itraconazole using *in vitro* data: A population-based approach, The 8<sup>th</sup> Iranian Students` Seminar in Europe, UMIST, Manchester, UK, 5-7 MAY 2001

**Heydari A.**, Rostami-Hodjegan A., Lennard M.S. Inactivation of CYP2D6 by ecstasy: Implications for frequency of dosage, The 9<sup>th</sup> Iranian Students` Seminar in Europe, UCE, Birmingham, 29-30 JUN 2002

### **Poster**

**Heydari A.**, Rostami-Hodjegan A., Lennard M.S., De La Torre R., Tucker G.T., Farre M., Inactivation of CYP450 2D6 by ecstasy: Implications for frequency of dosage (Harrogate), *Journal of Psychopharmacology* 16 (3): OT7 Suppl. S SEP 2002

**Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Lennard M.S., Ellis S.W., Tucker G.T. Mechanism-based inactivation of yeast expressed CYP2D6 by Ecstasy (MDMA), The proceeding of 6th Congress of the European Association for Clinical Pharmacology and Therapeutics” Istanbul (Turkey), JUN 24-28, 2003.

**Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Lennard M.S., Tucker G.T., Mechanism-based inactivation of yeast expressed CYP2D6 by ecstasy (MDMA), (Cambridge), *Journal of Psychopharmacology* 17 (3): A36-A36 Suppl. S SEP 2003

**Heydari A.**, Rostami-Hodjegan A., Lennard M.S., Farre M., Roset P. R., De La Torre R., Tucker G.T., Inactivation of CYP2D6 by ecstasy: Implication for frequency of dosage (Brighton), *British Journal of Clinical Pharmacology*, 55 (4): 430–430 APR 2003

**Heydari A.**, Rostami-Hodjegan A., Rowland-Yeo K., Lennard M.S., Tucker G.T., Methadone is not a mechanism-based inhibitor of cytochrome P450 2D6 (London) *British Journal of Clinical Pharmacology* 57 (5): 687-687 MAY 2004

Van L.M., Yang J.S., **Heydari A.**, Hargreaves J., Wade L., Coleman T. Rostami-Hodjegan A., Correcting for auto-inhibition via mechanism-based inactivation when assessing *in vitro* drug metabolism data, (Newcastle), *British Journal of Clinical Pharmacology* 14-16 DEC 2004.

**Heydari A.**, Rowland Yeo K., Lennard M.S., Tucker G.T., Rostami-Hodjegan A., The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition, European Issx Meeting at the Pharmscifair, Nice (France) JUN 12-17, 2005

Yang J.S., Jamei M., **Heydari A.**, Rowland Yeo K., De la Torre R., Farre M., Tucker G.T., Rostami-Hodjegan A., Mechanism-based inhibition of CYP2D6 by MDMA and its implications for pharmacokinetics and toxicity, *Journal of clinical pharmacology*, 45 (9): 1094-1094 113 SEP 2005

**Heydari A.**, Rowland Yeo K., Tucker G.T., Rostami-Hodjegan A. Prediction of *in vivo* drug-drug interactions involving selective serotonin reuptake inhibitors (SSRI'S) from *in vitro* data using Simcyp software, ISSX, Manchester 2006

**Heydari A.**, Inactivation of CYP450 2D6 by Ecstasy, Implications for the Pharmacokinetics and Frequency of Usage, International Symposium on Modeling & Simulation in Drug Development and Clinical Applications, Severance Hospital Yonsei University Medical Center, Seoul, Korea, 15-16 November 2006

**Heydari A.**, Inactivation of CYP450 2D6 by Ecstasy, Islamic Azad University of Astara, 21 December 2006, Astara, Iran

**Heydari A.**, Using Simulation to predict *in vivo* drug-drug interaction from *in vitro* data, 18<sup>th</sup> Iranian Congress of Physiology and Pharmacology, 26-30 August 2007 Mashhad, Iran

**Heydari A.**, Drug – Drug interactions mediated by Mechanism Based Inhibition (MBI), The 11<sup>th</sup> Iranian Pharmaceutical Sciences Conference (IPSC 2008), 18-21 August 2008 Kerman, Iran

**Heydari A.**, Rostami-Hodjegan A., Lennard M.S., Farre M., Roset P. R., De La Torre R., Tucker G.T., Inactivation of CYP2D6 by ecstasy: Implications for frequency of dosage and genotype-phenotype correlation, EUFEPS Satellite Stockholm, PKUK (Sweden), OCT 17-19,2002

**Heydari A.**, Yang J.S., Rostami-Hodjegan A., PBPK model for inactivation of CYP2D6 by MDMA: Implication for frequency of dosage, DMDG Meeting, Durham, SEPT 2002

**Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Lennard M.S. Ecstasy (MDMA) is a mechanism-based inhibitor of CYP2D6, The 10<sup>th</sup> Iranian Students` Seminar in Europe, Cambridge 31 MAY 2003

**Heydari A.**, Shiran M.R., Rstami-Hodjegan A., Lennard M.S., Tucker G.T., Plasma protein binding of Ecstasy and Methadone, PKUK Liverpool, 2003

**Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Lennard M.S., Ellis S.W., Tucker G.T., Ecstasy (MDMA) is a mechanism-based inhibitor of CYP2D6: Comparison of results from human liver microsomes and CYP2D6 expressed system, DMDG Meeting Warwick University, 2003

Yang J.S., **Heydari A.**, Rowland Yeo K., Rostami-Hodjegan A., Tucker G.T., Mechanism based inhibition of CYP2D6 by MDMA: Implications for the pharmacokinetics of MDMA, DMDG Meeting Warwick University, 2003

**Heydari A.**, Shiran M.R., Rstami-Hodjegan A., Lennard M.S., Tucker G.T., Plasma protein binding of Ecstasy and Methadone, The 12<sup>th</sup> Iranian Students Seminar in Europe UMIST, Manchester, UK, 3-4 JUL 2004

**Heydari A.**, Rowland Yeo K., Lennard M.S., Tucker G.T., Rostami-Hodjegan A., The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition, The 13<sup>th</sup> Iranian Students` Seminar in Europe, Leeds University UK, 2-3 JUL 2005

## **SKILLS**

IT Skills

English Language

